Figure 3.
Results from Princess Margaret Hospital in Toronto, Ont: Kaplan-Meier plot of PRFS as a function of time since implant for 776 men with iodine-125 PB for low-risk (85%) or intermediate-risk (5%) prostate cancer with more than 3 years’ follow-up.
PB—prostate brachytherapy, PRFS—PSA relapse-free survival, PSA—prostate-specific antigen.
Data from Crook et al.24
